There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
The president also said he "offered to personally vouch" for Rocky's bail. Sweden, however, does not have a bail system.Politicsread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
"This meeting tends to make major waves in the health care stocks," the "Mad Money " host said. "The problem is the announcements from these pharma and biotech companies often read like they're written in hieroglyphics. It can be very difficult to understand this stuff without a medical degree or a PhD in chemistry."
So, to help investors make sense of what often proves to be a groundbreaking event, Cramer went through the biggest winners and losers from J.P. Morgan's San Francisco, California-based health care convention.
Coming in first in terms of stock performance was Atara Biotherapeutics, up 52 percent since the start of 2018. Most of its move came after the J.P. Morgan conference.
The cause? Atara, a small company that develops immunotherapy treatments for cancer and multiple sclerosis, announced that the FDA approved one of its multiple sclerosis drugs for a Phase 1 study.
Better yet, Atara has a treatment for the Epstein-Barr virus (which causes mononucleosis, or mono) in Phase 3 trials — one step away from an FDA review.
"Put it all together, though, and it feels like the investors are warming to speculative biotechs again, even with the tape showing signs of raggedness today," Cramer said on Tuesday.
Up 47 percent for the year, Alder Biopharmaceuticals was the conference's second-biggest winner. Another small, development-stage biotechnology player, Alder announced strong clinical trial outcomes for its top medication, a migraine prevention drug.
"I like the story that CEO Randall Schatzman told us last week, " Cramer said. "But remember, Alder's still a very early-stage company and there are plenty of pitfalls remaining before FDA approval, including, by the way, the fact that some competitors are ahead of them in the process."
Other notable winners include Coherus Biosciences, a generic drugmaker with a 43 percent gain, and Illumina, a DNA-sequencing play up over 10 percent after the company introduced a new, low-cost sequencing machine.
(Cramer did caution investors about Coherus, which he saw as a commodity business with no patent protection.)
The J.P. Morgan Healthcare Conference's biggest loser by far was Axovant Sciences, a company working on treatments for Alzheimer's disease and dementia.
Cramer has watched Axovant's stock get totally decimated in recent months, the first wave of losses coming after the Phase 3 clinical trial for its lead drug missed the mark.
The second negative wave came after the same drug failed to reach its primary endpoint in studies for treating dementia; the third came after Axovant announced that it had wrongly released positive data about a separate treatment for hallucinations.
"That's how a stock goes from $5 to $2," Cramer said. "I think this is a powerful reminder of what happens when you buy a stock without doing the homework, especially when you're dealing with a overly promotional management team."
Tesaro, which makes cancer-related drugs, came in second among the losers, with a stock down more than 20 percent since the beginning of 2018.
Cramer attributed the decline to the fact that Tesaro recently had to change the label on one of its treatments for chemotherapy-induced nausea to include that one of its side effects was anaphylactic shock — a life-threatening allergic reaction.
Next up for the biggest losers was Clovis Oncology, another cancer treatment maker with a stock down big for no real reason, the "Mad Money" host said.
"There wasn't really anything particularly bad about the presentation," Cramer said. "In fact, Clovis had a lot of good things going on for it, especially when it comes to treating ovarian cancer and solid tumors, yet it can't seem to get any credit from Wall Street. That's intriguing."
Shares of Incyte got hit hard after the conference, but the company didn't report any bad news. Cramer said the real problem was that health care giant Celgene is buying Incyte's competitor, Impact Biomedicines, and the budding rivalry pushed investors out of Incyte's stock.
Cramer was also keeping a hawk's eye on Allergan after a tough 2017 for the Botox maker. But even after the company gave Wall Street weaker-than-expected guidance, the stock still managed to rally.
"CEO Brent Saunders painted a very compelling longer-term vision of the company's future in his presentation. Suddenly, Allergan seems to be getting traction again," Cramer said. "We just need to hear something that gives investors a reason to buy the stock beyond the fact that it's cheap."
The stock of Intuitive Surgical, the biotech behind the innovative da Vinci surgical robot, is also surging after a positive earnings pre-announcement. Cramer said he would stick with that name.
"Here's the bottom line: we got a lot of good news from the J.P. Morgan Healthcare Conference last week, but if this confab showed us one thing, it's that you need to be very careful when you speculate in small-cap biotech stocks, because the difference between the biggest winners and the biggest losers is enormous," the "Mad Money" host concluded.